Citigroup downgraded Mylan, Inc. (NASDAQ:MYL) to Neutral citing a lack of near-term catalysts ahead of the tax inversion deal closing. Citi lowered its price target for shares to $57 from $61. Mylan, Inc. (NASDAQ:MYL)’s stock on 30 July traded at beginning with a price of $50.77and when day-trade ended the stock finally moved up 0.30% to end at $50.55. Mylan, Inc. (NASDAQ:MYL)’s showed weekly performance of -3.42%.

Weyerhaeuser Co. (NYSE:WY) is scheduled to report its second-quarter 2014 results on Aug 1 before the market opens. The Zacks Consensus Estimate for the quarter is pegged at 34 cents per share. Weyerhaeuser Co. (NYSE:WY) on Wednesday closed at $31.82. Stock institutional ownership is 93.30% while insider ownership includes 0.20%. Weyerhaeuser Co. (NYSE:WY) distance from 50-day simple moving average (SMA50) is 0.30%.

On Thursday, July 24, 2014, First Merchants Corporation (NASDAQ:FRME) will conduct a second quarter earnings conference call and web cast on at 2:30 p.m. (ET). A copy of the slide presentation utilized on the conference call is furnished as Exhibit 99.1 to this Current Report on Form 8-K. First Merchants Corporation (NASDAQ:FRME)’s shares on Wednesday traded in the range of 19.926 – 20.24and ended up on $20.17. First Merchants Corporation (NASDAQ:FRME) distance from 200-day simple moving average (SMA200) is -2.51%. FRME’s sales growth for past 5 years was -4.90% and its EPS growth for past 5 years was 4.20%.

Applied Genetic Technologies Corporation (NASDAQ:AGTC) was a big mover last session, as the company saw its shares shoot up over 15% on the day. This significant rally higher can be attributable to solid volume with far more shares changing hands than in a normal session. This reverses the recent downtrend for the company as the stock is now down about 22.55% in the past one-month time frame. Applied Genetic Technologies Corporation (NASDAQ:AGTC)’s stock on 30 July moved up 3.56% to the closing price of $16.87. Its fifty two weeks range is $11.10 – 34.37. The total market capitalization recorded $271.3M. Applied Genetic Technologies Corporation (NASDAQ:AGTC) monthly performance is -26.97%.

Regulus Therapeutics Inc. (NASDAQ:RGLS) a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the quarter ended June 30, 2014 on Wednesday, August 6, 2014, after the U.S. financial markets close. Regulus Therapeutics Inc. (NASDAQ:RGLS) on Wednesday closed at $6.62. Stock institutional ownership is 32.70% while insider ownership includes 14.30%. Regulus Therapeutics Inc. (NASDAQ:RGLS) distance from 50-day simple moving average (SMA50) is -6.69%.